{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:27:15Z","timestamp":1780540035734,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation)"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ijid.2016.12.027","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T02:04:16Z","timestamp":1483754656000},"page":"122-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Minimum inhibitory concentration distributions for Mycobacterium avium complex\u2014towards evidence-based susceptibility breakpoints"],"prefix":"10.1016","volume":"55","author":[{"given":"Thomas","family":"Sch\u00f6n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erja","family":"Chryssanthou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2016.12.027_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2016.12.027_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-2600(15)00033-8","article-title":"Treatment of pulmonary disease caused by non-tuberculous mycobacteria","volume":"3","author":"van Ingen","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2016.12.027_bib0015","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2016.12.027_bib0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/jac\/dkv145","article-title":"The 2014 Garrod Lecture: EUCAST\u2014are we heading towards international agreement?","volume":"70","author":"Kahlmeter","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2016.12.027_bib0025","unstructured":"Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard\u2014second edition. CLSI document M24-A2 2011. Wayne, PA: CLSI."},{"key":"10.1016\/j.ijid.2016.12.027_bib0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijid.2016.12.027_bib0035","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2016.12.027_bib0040","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1128\/AAC.02995-14","article-title":"Intra- and extracellular activities of trimethoprim\u2013sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis","volume":"58","author":"Davies Forsman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2016.12.027_bib0045","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.ijid.2016.12.027_bib0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2471\/BLT.11.096644","article-title":"Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis","volume":"90","author":"Angeby","year":"2012","journal-title":"Bull World Health Organ"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T03:52:44Z","timestamp":1536119564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971217300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":10,"alternative-id":["S1201971217300024"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2016.12.027","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimum inhibitory concentration distributions for Mycobacterium avium complex\u2014towards evidence-based susceptibility breakpoints","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2016.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}